LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Lotte-Biologics-DCAT

More Like This

PR Newswire associated0

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

PR Newswire associated0

LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus

PR Newswire associated0

LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital

PR Newswire associated0

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

PR Newswire associated0

Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program

Nu-Tek BioSciences to Highlight Animal-Origin-Free Peptones, Supply Chain Strength at DCAT Week 2026

PR Newswire associated0

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market